In Vitro Toxicity Testing: Technologies and Global Markets

Report Highlights

The global in vitro toxicity testing market was valued at $4 billion in 2011 and more than $4.9 billion in 2012. This market is estimated to reach nearly $9.9 billion in 2017, with a compound annual growth rate (CAGR) of 14.7% for the five-year period, 2012 to 2017.

Report Includes

• An overview of the global in vitro toxicity testing market, with assessments of its growth potential over the next five years and the current market scenario for alternative measures to animal testing.
• Analyses of market trends, with data from 2011 and 2012, and projections of CAGRs for the period 2012 and 2017.
• Discussion of the two major technology-based approaches, mechanistic and nonmechanistic.
• A breakdown of influential factors, such as validation of the alternative measures for toxicity and toxicity testing strategies for chemicals, pesticides, and food additives.
• Profiles of major players in the industry

SCOPE OF REPORT

The scope of the report encompasses the major types of traditional toxicity testing that have been used, and the in vitro techniques that are being developed by industry, government agencies and nonprofits. It analyzes current market status, examines drivers on future markets and presents forecasts of growth over the next five years.

Technology developments, including the latest trends, are discussed. Other influential factors such as validation and testing strategies for pharmaceuticals, cosmetics, and chemicals have also been included.

Regulatory drivers play a large role in toxicology, determining the specific parameters of tests that have been explicitly required. They also heavily influence the testing that is performed by companies in earlier stages of research. The report examines the regulatory role and the different federal and international agencies that play an active role in in vitro toxicology research, development and adoption.

The term ‘predictive’ is often used in conjunction with in vitro toxicology, and historically predictive approaches (also called ‘nonmechanistic’) have been contrasted with mechanistic approaches. This report does discuss where applicable the relative magnitude of the two. However, our research shows that increasingly the two are used in tandem, and that they are being viewed as complementary parts of an overall toolkit. Thus, our use of the term ‘Predictive Toxicology’ as a subject/discipline throughout is intended to encompass both predictive and mechanistic, and to connote an evolution of the overall toolkit. In keeping with the ‘Tox 21’ vision detailed later, the key attribute of this overall evolution is being more and more able to use in vitro methods to predict in vivo outcomes.

Relative to the pharmaceutical industry, this report covers the testing of pharmaceutical or so-called ‘small molecule’ drugs, synthesized from chemical compounds. Biologics, so-called ‘large molecule’ drugs, are tested via completely different approaches and technologies. Biologics safety testing is outside the scope of this report.

Analyst Credentials

Robert Hunter is a senior management consultant, commercialization consultant and technology and market analyst with over 20 years of experience in life sciences and healthcare. Recent consulting includes market/technology analysis and forecasting of customer adoption and revenue for a high content screening (HCS) technology leader. He is an early investor in a company using stem cells for predictive drug safety testing in vitro. He has a B.S. in Mechanical Engineering from Clemson University and Master of Business Administration from The Tuck School of Business at Dartmouth.